𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR positive advanced colorectal cancer treated with gefitinib?

✍ Scribed by M. G. Zampino; E. Magni; L. Santoro; L. Zorzino; P. Dell’Orto; A. Sonzogni; N. Fazio; L. Monfardini; A. Chiappa; R. Biffi; F. de Braud

Publisher
Springer
Year
2008
Tongue
English
Weight
397 KB
Volume
63
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Epidermal growth factor receptor mutatio
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
✍ Jin-Yuan Shih; Chien-Hung Gow; Chong-Jen Yu; Chih-Hsin Yang; Yih-Leong Chang; Me 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 161 KB 👁 2 views

## Abstract Recently, mutations in the __epidermal growth factor receptor__ (__EGFR__) gene in nonsmall cell lung cancer (NSCLC) patients were reported to correlate with gefitinib response. Less than 30% of NSCLC patients are surgically resectable; however, molecular analysis has to rely on nonsurg

Detection of epidermal growth factor rec
Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer
✍ Chen He; Ming Liu; Chengzhi Zhou; Jiexia Zhang; Ming Ouyang; Nanshan Zhong; Jun 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 260 KB 👁 2 views

## Abstract The high frequency of epidermal growth factor receptor (__EGFR__) mutations in tyrosine kinase inhibitor‐responsive non‐small‐cell lung cancer (NSCLC) cases is now well established, highlighting the predictive value of activating __EGFR__ mutations in guiding the clinical use of __EGFR_

Usefulness of monitoring the circulating
Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
✍ Nobuhisa Ishikawa; Noboru Hattori; Akihoto Yokoyama; Sonosuke Tanaka; Ryohei Nis 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 289 KB 👁 2 views

## Abstract Krebs von den Lungen‐6 (KL‐6) is a high molecular weight glycoprotein classified in the category of human MUC1 mucin. KL‐6 has been reported to serve as a sensitive marker for interstitial pneumonia; however, recent studies have suggested that it can also be used as a tumor marker as it